Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males - A Sub-study of HPTN 083

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Adverse reactions; Therapeutic Use

15 Aug 2023 Status changed from active, no longer recruiting to completed.
08 Nov 2022 Planned End Date changed from 31 May 2023 to 31 Aug 2023.
08 Nov 2022 Planned primary completion date changed from 31 May 2023 to 31 Aug 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com